X
Search
X

Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.

X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

AAA Doses First Patients in Two Clinical Studies with PSMA-R2 for Prostate Cancer

Advanced Accelerator Applications S.A. (AAA), today announced that the first patients have been dosed in two clinical studies of radiolabeled PSMA-R2, a urea-based ligand of Prostate-Specific Membrane Antigen (PSMA), which is commonly expressed on prostate cancer cells. Primary objectives for Phase I include characterizing the drug’s safety profile and tolerability, as well identifying a recommended Phase II dose. The primary objective for Phase II is assessment of antitumor activity, as measured by radiographic progression-free survival.

Read more. 

source: News Medical